Patents by Inventor Shunpei Ishikawa
Shunpei Ishikawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10851079Abstract: The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis, multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.Type: GrantFiled: February 27, 2017Date of Patent: December 1, 2020Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yoshikazu Kawano, Hiroshi Shimizu, Shunpei Ishikawa, Isao Takemura, Norimitsu Hariguchi, Miki Matsuba, Makoto Matsumoto
-
Patent number: 10696743Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.Type: GrantFiled: February 10, 2017Date of Patent: June 30, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
-
Patent number: 10464926Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.Type: GrantFiled: July 9, 2018Date of Patent: November 5, 2019Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Shimizu, Yoshikazu Kawano, Shunpei Ishikawa, Yukitaka Uematsu, Toshio Shinohara, Motohiro Itotani, Yoshikazu Haraguchi, Isao Takemura, Atsunori Kaneshige, Yuya Nakai, Norimitsu Hariguchi, Yohei Hayashi, Makoto Matsumoto
-
Publication number: 20190040039Abstract: The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis, multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.Type: ApplicationFiled: February 27, 2017Publication date: February 7, 2019Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yoshikazu KAWANO, Hiroshi SHIMIZU, Shunpei ISHIKAWA, Isso TAKEMURA, Norimitsu HARIGUCHI, Miki MATSUBA, Makoto MATSUMOTO
-
Publication number: 20180312488Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.Type: ApplicationFiled: July 9, 2018Publication date: November 1, 2018Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi SHIMIZU, Yoshikazu KAWANO, Shunpei ISHIKAWA, Yukitaka UEMATSU, Toshio SHINOHARA, Motohiro ITOTANI, Yoshikazu HARAGUCHI, Isao TAKEMURA, Atsunori KANESHIGE, Yuya NAKAI, Norimitsu HARIGUCHI, Yohei HAYASHI, Makoto MATSUMOTO
-
Patent number: 10053446Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.Type: GrantFiled: August 28, 2015Date of Patent: August 21, 2018Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Shimizu, Yoshikazu Kawano, Shunpei Ishikawa, Yukitaka Uematsu, Toshio Shinohara, Motohiro Itotani, Yoshikazu Haraguchi, Isao Takemura, Atsunori Kaneshige, Yuya Nakai, Norimitsu Hariguchi, Yohei Hayashi, Makoto Matsumoto
-
Publication number: 20170253576Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.Type: ApplicationFiled: August 28, 2015Publication date: September 7, 2017Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Hiroshi SHIMIZU, Yoshikazu KAWANO, Shunpei ISHIKAWA, Yukitaka UEMATSU, Toshio SHINOHARA, Motohiro ITOTANI, Yoshikazu HARAGUCHI, Isao TAKEMURA, Atsunori KANESHIGE, Yuya NAKAI, Norimitsu HARIGUCHI, Yohei HAYASHI, Makoto MATSUMOTO
-
Publication number: 20170152314Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Inventors: Hiroyuki ABURATANI, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
-
Patent number: 9139647Abstract: The present invention relates to an antibody binding to a TM4SF20 protein and the diagnosis and treatment of cancer using the antibody. Specifically, the present invention provides an anti-TM4SF20 antibody and a pharmaceutical composition (e.g., an anticancer agent and a diagnostic drug for cancer) comprising the antibody as an active ingredient.Type: GrantFiled: December 25, 2009Date of Patent: September 22, 2015Assignees: FORERUNNER PHARMA RESEARCH CO., LTD., THE UNIVERSITY OF TOKYOInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Shigeto Kawai
-
Patent number: 9079957Abstract: [Problem to be Solved] An object of the present invention is to provide novel means for the treatment and diagnosis of cancer. [Solution] The present inventors have obtained a monoclonal antibody against TMPRSS11E and found that this antibody binds to a native form of TMPRSS11E, and TMPRSS11E is highly expressed on the cell membranes of cancer cell lines in flow cytometry. This antibody exhibits antibody-dependent cell-mediated cytotoxicity activity (ADCC activity) and antitumor effect based on internalization activity and is promising as a therapeutic target. Moreover, this antibody has neutralization activity against protease activity and is also expected to have effect brought about by the inhibition of TMPRSS11E functions.Type: GrantFiled: April 15, 2010Date of Patent: July 14, 2015Assignees: THE UNIVERSITY OF TOKYO, FORERUNNER PHARMA RESEARCH CO., LTD.Inventors: Hiroyuki Aburatani, Shunpei Ishikawa, Kiyotaka Nakano
-
Publication number: 20120128678Abstract: [Problem to be Solved] An object of the present invention is to provide novel means for the treatment and diagnosis of cancer. [Solution] The present inventors have obtained a monoclonal antibody against TMPRSS11E and found that this antibody binds to a native form of TMPRSS11E, and TMPRSS11E is highly expressed on the cell membranes of cancer cell lines in flow cytometry. This antibody exhibits antibody-dependent cell-mediated cytotoxicity activity (ADCC activity) and antitumor effect based on internalization activity and is promising as a therapeutic target. Moreover, this antibody has neutralization activity against protease activity and is also expected to have effect brought about by the inhibition of TMPRSS11E functions.Type: ApplicationFiled: April 15, 2010Publication date: May 24, 2012Applicants: Forerunner Pharma Research Co., Ltd., The University of TokyoInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Kiyataka Nakano
-
Publication number: 20120004117Abstract: The present invention relates to an antibody binding to a TM4SF20 protein and the diagnosis and treatment of cancer using the antibody. Specifically, the present invention provides an anti-TM4SF20 antibody and a pharmaceutical composition (e.g., an anticancer agent and a diagnostic drug for cancer) comprising the antibody as an active ingredient.Type: ApplicationFiled: December 25, 2009Publication date: January 5, 2012Applicants: Forerunner Pharma Research Co., Ltd., The University of TokyoInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Shigeto Kawai
-
Publication number: 20100092457Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.Type: ApplicationFiled: August 14, 2007Publication date: April 15, 2010Applicants: Forerunner Pharma Research Co., Ltd., The University of TokyoInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
-
Publication number: 20060135750Abstract: With the object of providing a novel protein expression of which is specifically elevated in abnormal cells or abnormal tissue, and also providing a diagnostic method and diagnostic kit for diseases involving elevated expression of a gene encoding that protein, along with a screening method and screening kit for substances for preventing and treating diseases involving elevated expression of a gene encoding that protein, (a) a protein comprising the amino acid sequence represented by Seq. ID No. 2 or (b) a protein comprising the amino acid sequence represented by Seq. ID No.Type: ApplicationFiled: June 24, 2005Publication date: June 22, 2006Applicants: TOUDAI TLO, Ltd., CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroyuki Aburatani, Hirotaka Ito, Shunpei Ishikawa, Shinichi Fukumoto